

DAC/JPW  
\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blake PEPINSKY, *et al.* Examiner: Fozia Hamud  
U.S. Pat. No.: 7,446,173 Serial No.: 10/802,540  
Issued: November 4, 2008 Filed: March 16, 2004  
Art Unit: 1647  
Title: POLYMER CONJUGATES OF INTERFERON BETA-1A AND USES

**Mail Stop Petition**

**Commissioner for Patents**

United States Patent and Trademark Office  
Office of Petitions  
Randolph Building  
401 Dulany Street  
Alexandria VA 22314

**PETITION FOR RECONSIDERATION OF PATENT TERM ADJUSTMENT UNDER 37**


**CFR 1.705(d)**

The undersigned hereby petitions under 37 CFR 1.705(d) to request reconsideration of the patent term adjustment as indicated on the cover of U.S. Patent No. 7,446,173. In accordance with 37 CFR 1.705(d), this petition is being filed within two months of the date the patent issued. Applicants further submit for consideration, a statement of the facts involved as required under 37 CFR 1.705(b)(2).

The Commissioner is authorized to charge \$200 to the Deposit Account 19-4293 for the petition fee as set forth in 37 CFR 1.18(e). Should this fee be in error, the Commissioner is hereby authorized to debit or credit Deposit Account 19-4293.

Respectfully submitted,

Date: 11-19-08  
Steptoe & Johnson LLP  
1330 Connecticut Avenue, NW  
Washington, DC 20036-1795  
Phone: 202-429-3000  
Fax: 202-429-3902

  
Harold H. Fox  
Reg. No. 41,498



UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blake PEPINSKY, *et al.* Examiner: Fozia Hamud  
U.S. Pat. No.: 7,446,173 Serial No.: 10/802,540  
Issued: November 4, 2008 Filed: March 16, 2004  
Art Unit: 1647  
Title: POLYMER CONJUGATES OF INTERFERON BETA-1A AND USES

**Mail Stop Petition**

United States Patent and Trademark Office  
Office of Petitions  
Randolph Building  
401 Dulany Street  
Alexandria VA 22314

**STATEMENT IN SUPPORT OF PETITION FOR RECONSIDERATION OF  
PATENT TERM ADJUSTMENT UNDER 37 CFR 1.705(d)**

The undersigned respectfully requests the reconsideration of the patent term adjustment ("PTA") for U.S. Patent No. 7,446,173 ("the '173 patent").

The term of the '173 patent has been extended by 502 days. The calculation for the current PTA calculated by the USPTO is 502 days based on 590 days of USPTO delay and 88 days of Applicant delay. See PTA calculation downloaded from PAIR, attached as Exhibit B.

Based on the recent decision in Wyeth v. Dudas, Civil Action No. 07-1492 (D.D.C. 2008) (attached as Exhibit A) patentees believe that patentees are entitled to an additional portion of patent term which amount to a total of **807 days**.

Support for the 807 days of PTA is justified as follows. Periods of delay that fall under 35 U.S.C. § 154 (b)(1)(A)(i)-(iv) are known as "A delays." "A delays" include "a one-day extension of patent term for every day that issuance of a patent is delayed by failure of the PTO to comply with various enumerated statutory deadlines: fourteen months for a first office action; ...." See slip op. at 3. Periods of delay that fall under 35 U.S.C. § 154 (b)(1)(B) are known as "B delays" and include "a one-day term extension [] for every day greater than three years after the filing date that it takes for the patent to issue, regardless of whether the delay is the fault of the PTO." See slip op. at 3. The A delays and B delays are subject to the limitations of 35 U.S.C. § 154(b)(2)(A) which state that "[t]o the extent that periods of delay attributable to grounds specified in paragraph

(1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the patent was delayed.” The court stated that “the PTO's view is that any administrative delay under § 154(b)(1)(A) overlaps any 3-year maximum pendency delay under § 154(b)(1)(B): the applicant gets credit for 'A delay' or for 'B delay,' whichever is larger, but never A + B.” See slip op. at 5. The court however, interpreted 35 U.S.C. § 154(b)(2)(A) and stated that “[t]he only way that [A and B] periods of time can ‘overlap’ is if they occur on the same day.” See slip op. at 8. Therefore, a patent holder is entitled to PTA which includes the period of “A delay” + “B delay.”

In accordance with the example provided by Wyeth v. Dudas, the undersigned provides the following calculation of PTA for consideration:

**“A delay”:**

May 16, 2005 (14 month date) to December 27, 2006 (mailing date of Restriction requirement) = **590 days**

**“B delay”:**

March 16, 2007 (3 years after patent application was filed) to November 4, 2008 (issue date) = **599 days**

**Applicants' Delay**

88 days (response to non-Final Office Action)

294 days (delay for 312 Amendment filed January 15, 2008) to date of issuance (November 4, 2008)


**Total PTA**

A delay + B delay – Applicants' Delay which is 590 days + 599 days – (88+294 days) which equals **807 days**.

For the reasons stated above, reconsideration of PTA is respectfully requested. Should any further fees be in error, the Commissioner is hereby authorized to debit or credit Deposit Account 19-4293.

Respectfully submitted,

Date: 11-19-08  
\_\_\_\_\_  
Steptoe & Johnson LLP  
1330 Connecticut Avenue, NW  
Washington, DC 20036-1795  
Phone: 202-429-3000  
Fax: 202-429-3902

  
\_\_\_\_\_  
Harold H. Fox  
Reg. No. 41,498

# **EXHIBIT A**



UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF COLUMBIA

WYETH, et al.,  
:  
:  
Plaintiffs,  
:  
:  
v. : Civil Action No. 07-1492 (JR)  
:  
JON W. DUDAS, Under Secretary of :  
Commerce for Intellectual :  
Property and Director of U.S. :  
Patent and Trademark Office, :  
:  
Defendant. :

MEMORANDUM OPINION

Plaintiffs here take issue with the interpretation that the United States Patent and Trademark Office (PTO) has imposed upon 35 U.S.C. § 154, the statute that prescribes patent terms. Section 154(a)(2) establishes a term of 20 years from the day on which a successful patent application is first filed. Because the clock begins to run on this filing date, and not on the day the patent is actually granted, some of the effective term of a patent is consumed by the time it takes to prosecute the application. To mitigate the damage that bureaucracy can do to inventors, the statute grants extensions of patent terms for certain specified kinds of PTO delay, 35 U.S.C. § 154(b)(1)(A), and, regardless of the reason, whenever the patent prosecution takes more than three years. 35 U.S.C. § 154(b)(1)(B). Recognizing that the protection provided by these separate guarantees might overlap, Congress has forbidden double-counting: "To the extent that periods of delay attributable to grounds

specified in paragraph (1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the patent was delayed." 35 U.S.C.

§ 154(b)(2)(A). Plaintiffs claim that the PTO has misconstrued or misapplied this provision, and that the PTO is denying them a portion of the term Congress has provided for the protection of their intellectual property rights.

### **Statutory Scheme**

Until 1994, patent terms were 17 years from the date of issuance. See 35 U.S.C. § 154 (1992) ("Every patent shall contain . . . a grant . . . for the term of seventeen years . . . of the right to exclude others from making, using, or selling the invention throughout the United States. . . ."). In 1994, in order to comply with treaty obligations under the General Agreement on Tariffs and Trade (GATT), the statute was amended to provide a 20-year term from the date on which the application is first filed. See Pub. L. No. 103-465, § 532, 108 Stat. 4809, 4984 (1994). In 1999, concerned that extended prosecution delays could deny inventors substantial portions of their effective patent terms under the new regime, Congress enacted the American Inventors Protection Act, a portion of which -- referred to as the Patent Term Guarantee Act of 1999 -- provided for the adjustments that are at issue in this case. Pub. L. No. 106-113, §§ 4401-4402, 113 Stat. 1501, 1501A-557 (1999).

As currently codified, 35 U.S.C. § 154(b) provides three guarantees of patent term, two of which are at issue here. The first is found in subsection (b) (1) (A), the "[g]uarantee of prompt Patent and Trademark Office response." It provides a one-day extension of patent term for every day that issuance of a patent is delayed by a failure of the PTO to comply with various enumerated statutory deadlines: fourteen months for a first office action; four months to respond to a reply; four months to issue a patent after the fee is paid; and the like. See 35 U.S.C. § 154(b) (1) (A) (i)-(iv). Periods of delay that fit under this provision are called "A delays" or "A periods." The second provision is the "[g]uarantee of no more than 3-year application pendency." Under this provision, a one-day term extension is granted for every day greater than three years after the filing date that it takes for the patent to issue, regardless of whether the delay is the fault of the PTO.<sup>1</sup> See 35 U.S.C. § 154(b) (1) (B). The period that begins after the three-year window has closed is referred to as the "B delay" or the "B period". ("C delays," delays resulting from interferences, secrecy orders, and appeals, are similarly treated but were not involved in the patent applications underlying this suit.)

---

<sup>1</sup> Certain reasons for exceeding the three-year pendency period are excluded, see 35 U.S.C. § 154(b) (1) (b) (i)-(iii), as are periods attributable to the applicant's own delay. See 35 U.S.C. § 154(b) (2) (C).

The extensions granted for A, B, and C delays are subject to the following limitation:

**(A) In general.**--To the extent that periods of delay attributable to grounds specified in paragraph (1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the patent was delayed.

35 U.S.C. § 154(b) (2) (A). This provision is manifestly intended to prevent double-counting of periods of delay, but understanding that intent does not answer the question of what is double-counting and what is not. Proper interpretation of this proscription against windfall extensions requires an assessment of what it means for "periods of delay" to "overlap."

The PTO, pursuant to its power under 35 U.S.C. § 154(b) (3) (A) to "prescribe regulations establishing procedures for the application for and determination of patent term adjustments," has issued final rules and an "explanation" of the rules, setting forth its authoritative construction of the double-counting provision. The rules that the PTO has promulgated essentially parrot the statutory text, see 37 C.F.R. § 1.703(f), and so the real interpretive act is found in something the PTO calls its Explanation of 37 CFR 1.703(f) and of the United States Patent and Trademark Office Interpretation of 35 U.S.C. § 154(b) (2) (A), which was published on June 21, 2004, at 69 Fed. Reg. 34238. Here, the PTO "explained" that:

the Office has consistently taken the position that if an application is entitled to an adjustment under the three-year pendency provision of 35 U.S.C. § 154(b)(1)(B), the entire period during which the application was pending before the Office (except for periods excluded under 35 U.S.C. § 154(b)(1)(B)(i)-(iii)), and not just the period beginning three years after the actual filing date of the application, is the relevant period under 35 U.S.C. § 154(b)(1)(B) in determining whether periods of delay "overlap" under 35 U.S.C. 154(b)(2)(A).

69 Fed. Reg. 34238 (2004) (emphasis added). In short, the PTO's view is that any administrative delay under § 154(b)(1)(A) overlaps any 3-year maximum pendency delay under § 154(b)(1)(B): the applicant gets credit for "A delay" or for "B delay," whichever is larger, but never A + B.

In the plaintiffs' submission, this interpretation does not square with the language of the statute. They argue that the "A period" and "B period" overlap only if they occur on the same calendar day or days. Consider this example, proffered by plaintiff: A patent application is filed on 1/1/02. The patent issues on 1/1/08, six years later. In that six-year period are two "A periods," each one year long: (1) the 14-month deadline for first office action is 3/1/03, but the first office action does not occur until 3/1/04, one year late; (2) the 4-month deadline for patent issuance after payment of the issuance fee is

1/1/07, but the patent does not issue until 1/1/08, another year of delay attributable to the PTO. According to plaintiff, the "B period" begins running on 1/1/05, three years after the patent application was filed, and ends three years later, with the issuance of the patent on 1/1/08. In this example, then, the first "A period" does not overlap the "B period," because it occurs in 2003-04, not in 2005-07. The second "A period," which covers 365 of the same days covered by the "B period," does overlap. Thus, in plaintiff's submission, this patent holder is entitled to four years of adjustment (one year of "A period" delay + three years of "B period" delay). But in the PTO's view, since "the entire period during which the application was pending before the office" is considered to be "B period" for purposes of identifying "overlap," the patent holder gets only three years of adjustment.

#### **Chevron Deference**

We must first decide whether the PTO's interpretation is entitled to deference under Chevron v. NRDC, 467 U.S. 837 (1984). No, the plaintiffs argue, because, under the Supreme Court's holdings in Gonzales v. Oregon, 546 U.S. 243 (2006), and United States v. Mead Corp., 533 U.S. 218 (2001), Congress has not "delegated authority to the agency generally to make rules carrying the force of law," and in any case the interpretation at issue here was not promulgated pursuant to any such authority.

See Gonzales, 546 U.S. at 255-56, citing Mead, 533 U.S. at 226-27. Since at least 1996, the Federal Circuit has held that the PTO is not afforded Chevron deference because it does not have the authority to issue substantive rules, only procedural regulations regarding the conduct of proceedings before the agency. See Merck & Co. v. Kessler, 80 F.3d 1543, 1549-50 (Fed. Cir. 1996).

Here, as in Merck, the authority of the PTO is limited to prescribing "regulations establishing procedures for the application for and determination of patent term adjustments under this subsection." 35 U.S.C. § 154(b)(3)(A) (emphasis added). Indeed, a comparison of this rulemaking authority with the authority conferred for a different purpose in the immediately preceding section of the statute makes it clear that the PTO's authority to interpret the overlap provision is quite limited. In 35 U.S.C. § 154(b)(2)(C)(iii) the PTO is given the power to "prescribe regulations establishing the circumstances that constitute a failure of an applicant to engage in reasonable efforts to conclude processing or examination of an application" (emphasis added) -- that is, the power to elaborate on the meaning of a particular statutory term. No such power is granted under § 154(b)(3)(A). Chevron deference does not apply to the interpretation at issue here.

### **Statutory Construction**

Chevron would not save the PTO's interpretation, however, because it cannot be reconciled with the plain text of the statute. If the statutory text is not ambiguous enough to permit the construction that the agency urges, that construction fails at Chevron's "step one," without regard to whether it is a reasonable attempt to reach a result that Congress might have intended. See, e.g., MCI v. AT&T, 512 U.S. 218, 229 (1994) ("[A]n agency's interpretation of a statute is not entitled to deference when it goes beyond the meaning that the statute can bear.").

The operative question under 35 U.S.C. § 154(b)(2)(A) is whether "periods of delay attributable to grounds specified in paragraph (1) overlap." The only way that periods of time can "overlap" is if they occur on the same day. If an "A delay" occurs on one calendar day and a "B delay" occurs on another, they do not overlap, and § 154(b)(2)(A) does not limit the extension to one day. Recognizing this, the PTO defends its interpretation as essentially running the "period of delay" under subsection (B) from the filing date of the patent application, such that a period of "B delay" always overlaps with any periods of "A delay" for the purposes of applying § 154(b)(2)(A).

The problem with the PTO's construction is that it considers the application delayed under § 154(b)(1)(B) during the

period before it has been delayed. That construction cannot be squared with the language of § 154(b)(1)(B), which applies "if the issue of an original patent is delayed due to the failure of the United States Patent and Trademark Office to issue a patent within 3 years." (Emphasis added.) "B delay" begins when the PTO has failed to issue a patent within three years, not before.

The PTO's interpretation appears to be driven by Congress's admonition that any term extension "not exceed the actual number of days the issuance of the patent was delayed," and by the PTO's view that "A delays" during the first three years of an applications' pendency inevitably lead to "B delays" in later years. Thus, as the PTO sees it, if plaintiffs' construction is adopted, one cause of delay will be counted twice: once because the PTO has failed to meet an administrative deadline, and again because that failure has pushed back the entire processing of the application into the "B period." Indeed, in the example set forth above, plaintiffs' calendar-day construction does result in a total effective patent term of 18 years under the (B) guarantee, so that -- again from the PTO's viewpoint -- the applicant is not "compensated" for the PTO's administrative delay, he is benefitted by it.

But if subsection (B) had been intended to guarantee a 17-year patent term and no more, it could easily have been written that way. It is true that the legislative context -- as

distinct from the legislative history -- suggests that Congress may have intended to use subsection (B) to guarantee the 17-year term provided before GATT. But it chose to write a "[g]uarantee of no more than 3-year application pendency," 35 U.S.C.

§ 154(b)(1)(B), not merely a guarantee of 17 effective years of patent term, and do so using language separating that guarantee from a different promise of prompt administration in subsection (A). The PTO's efforts to prevent windfall extensions may be reasonable -- they may even be consistent with Congress's intent -- but its interpretation must square with Congress's words. If the outcome commanded by that text is an unintended result, the problem is for Congress to remedy, not the agency.

JAMES ROBERTSON  
United States District Judge



UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF COLUMBIA

WYETH, et al., :  
 :  
 Plaintiffs, :  
 :  
 v. : Civil Action No. 07-1492 (JR)  
 :  
 JON W. DUDAS, Under Secretary of :  
 Commerce for Intellectual :  
 Property and Director of U.S. :  
 Patent and Trademark Office, :  
 :  
 Defendant. :

ORDER

For the reasons stated in the accompanying memorandum opinion, plaintiffs' motion for summary judgment [12] is **GRANTED** and defendant's motion for summary judgment [16] is **DENIED**. The case is remanded to the agency for further proceedings that are consistent with this opinion.

JAMES ROBERTSON  
United States District Judge